Rosacea: From Origins to Outcomes
Proceedings From an Expert Roundtable Meeting

July 2003
Chicago, Illinois

Supported by an independent grant from Galderma Laboratories, L.P.

Guest Editors:
John E. Wolf, Jr, MD, and James Q. Del Rosso, DO

Introduction
John E. Wolf, Jr, MD
Baylor College of Medicine, Houston, Texas

Rosacea as an Inflammatory Disorder: A Unifying Theory?
Larry E. Millikan, MD
Tulane University Health Sciences Center, New Orleans, Louisiana
The Subtypes of Rosacea: Implications for Treatment  
Richard B. Odom, MD  
University of California, San Francisco  

Mechanism-Based Selection of Pharmacologic Agents for Rosacea  
Alan Shalita, MD  
State University of New York, Downstate Medical Center, Brooklyn  
James Leyden, MD  
University of Pennsylvania, Philadelphia  

The Role of Topical Metronidazole in the Treatment of Rosacea  
John E. Wolf, Jr, MD  
Baylor College of Medicine, Houston, Texas  

Evaluating the Role of Topical Therapies in the Management of Rosacea: Focus on Combination Sodium Sulfacetamide and Sulfur Formulations  
James Q. Del Rosso, DO  
University of Nevada School of Medicine, Las Vegas  

Roundtable Discussion: The Treatment of Rosacea  
James Q. Del Rosso, DO  
John E. Wolf, Jr, MD  
James Leyden, MD  
Larry E. Millikan, MD  
Richard B. Odom, MD  
Alan Shalita, MD